HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latisse Eyelash Stimulant Will Complement, Not Supplant, Mascara – Allergan

This article was originally published in The Rose Sheet

Executive Summary

Allergan does not expect sales of its eyelash growth drug Latisse to take significant market share from mascara makers

You may also be interested in...



FDA Cites Latisse Web Site For Implying Eyelash Growth Drug Is A Cosmetic

Allergan's consumer Web site for its eyelash growth drug Latisse certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic

FDA Cites Latisse Web Site For Implying Eyelash Growth Drug Is A Cosmetic

Allergan's consumer Web site for its eyelash growth drug Latisse certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic

Image Skincare Undercuts Competition With $89 Ageless Lashes

Image Skincare is touting its new Ageless Lashes as an eyelash growth product that not only offers eye-line color but also costs less than competing products, prescription and otherwise

Related Content

UsernamePublicRestriction

Register

RS015949

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel